By Kane Wu
HONG KONG (Reuters) – International non-public fairness companies Blackstone (NYSE:) and Bain Capital are amongst ultimate bidders for Mitsubishi Tanabe Pharma, a unit of Japan’s Mitsubishi Chemical Group, in a deal that might worth it at between $3 billion and $3.5 billion, three sources mentioned.
Mitsubishi Chemical has employed Goldman Sachs to run the sale course of and binding bids are due on Dec. 24, the sources mentioned.
Native non-public fairness agency Japan Industrial Companions (JIP) can also be bidding for the corporate, mentioned the sources, who all declined to be named as the data was confidential.
Blackstone, Bain Capital, Goldman Sachs and Mitsubishi Chemical declined to remark. Tanabe referred Reuters request for remark to its guardian firm.
Representatives for JIP couldn’t be reached and the agency didn’t reply to a written request for remark submitted through its web site.
Mitsubishi Chemical mentioned in September, in response to a information report in regards to the Tanabe sale, that the group is repeatedly reviewing the perfect enterprise portfolio for all companies, together with pharma, and exploring all choices together with divestiture.
Arrange over 90 years in the past, Osaka-based Tanabe’s pipeline features a vary of medication for the central nervous system, immuno-inflammation and oncology. It has items in additional than a dozen places throughout three continents outdoors Japan, its web site confirmed.
Within the first half of the fiscal 12 months to end-March, 2025 Mitsubishi Chemical’s pharma section reported a 6% improve in gross sales income to 232.5 billion yen and a 28% rise in core working earnings to 41.4 billion yen, in accordance with group disclosures.
